Long Valley, NJ, United States of America

Alan K Mallams

This inventor holds 61 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 4 EPO patents, primarily in Cyclin Dependent Kinase Inhibitors (CPC class 5142). Top assignees: Schering Corporation, Pharmacopeia Inc., Pharmacopeia Drug Discovery, Inc.. Active years: 1976-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alan K Mallams. Retrieved from https://idiyas.com/inventor/alan-k-mallams

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 61 

% Patents Active = 85.2


 

Average Co-Inventor Count = 4.0

ph-index = 17

Forward Citations = 688(Granted Patents)

Forward Citations (Not Self Cited) = 647(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • West Orange, NJ (US) (1976 - 1990)
  • Long Valley, NJ (US) (1997 - 2002)
  • Hackettstwon, NJ (US) (2005)
  • Mallams, NJ (US) (2005)
  • Hackettstown, NJ (US) (1997 - 2014)

Company Filing History:


Years Active: 1976-2014

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Cyclin Dependent Kinase
Farnesyl Protein Transferase
G-Protein Function
Pyrazolopyrimidines
Imidazopyrazines
Tricyclic Compounds
Urea Inhibitors
Proliferative Diseases
p53 Modulators
Androgen Dependent Diseases
Heteroaryl Compounds
61 patents (USPTO):Explore Patents

Title: Innovations of Alan K Mallams: A Prominent Contributor to Cyclin Dependent Kinase Research

Introduction: Alan K Mallams, based in Long Valley, NJ, has made significant strides in the field of biochemistry through his inventive contributions. With a remarkable portfolio of 61 patents, Mallams has established himself as an influential inventor, particularly in the area of cyclin dependent kinase (CDK) inhibitors.

Latest Patents: Among his latest inventions are his patents concerning substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors. This innovation provides methods for inhibiting one or more cyclin dependent kinases in patients by administering a therapeutically effective amount of certain pyrazolo[1,5-a]pyrimidine compounds. This compound is crucial in the treatment, prevention, inhibition, or amelioration of diseases associated with CDKs. Another notable patent involves N-heteroaryl pyrazolopyrimidines, which comprise a novel class of pyrazolo[1,5-a]pyrimidine compounds serving as inhibitors of cyclin dependent kinases. His methods include the preparation of these compounds and their formulations for therapeutic use.

Career Highlights: Throughout his career, Alan K Mallams has collaborated with renowned companies in the pharmaceutical sector, including Schering Corporation and Pharmacopeia Inc. His work has placed him at the forefront of innovative drug development, particularly focusing on oncology and related diseases.

Collaborations: In addition to his impressive individual achievements, Mallams has worked alongside talented colleagues such as Ronald J Doll and F George Njoroge. Together, they have contributed to advancing scientific knowledge and therapeutic methodologies, showcasing the power of collaboration in innovation.

Conclusion: Alan K Mallams exemplifies the dynamic impact that inventors can have on the medical field through innovation. His extensive patent portfolio and collaborative efforts reflect a commitment to advancing healthcare solutions, particularly through the development of cyclin dependent kinase inhibitors. His work continues to inspire upcoming inventors and researchers in the biomedical community.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…